지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한정신약물학회 Clinical Psychopharmacology and Neuroscience Clinical Psychopharmacology and Neuroscience 제19권 제3호
- 발행연도
- 2021.8
- 수록면
- 459 - 469 (11page)
- DOI
- 10.9758/cpn.2021.19.3.459
이용수
초록· 키워드
오류제보하기
Objective: The purpose of this study is to investigate the safety, tolerability and efficacy of titrating dose of rivastigmine oral solution in patients with mild to moderate Alzheimer’s disease (AD) in Taiwan.
Methods: We recruited 108 mild to moderate AD patients with Rivastⓡ (rivastigmine oral solution 2 mg/ml) treatment for 52 weeks. We recorded the demographic characteristics, initial cognition by mini-mental state examination (MMSE), initial global status by clinical dementia rating (CDR) with CDR-Sum of Boxes (CDR-SB), initial dose, and titrating dose at each visit. We investigated the adherence, proportion of possible side effects, optimal dose, and time to optimal dose. We demonstrated the proportion of cognitive decline and its possible risk factors.
Results: During the course, 9 patients discontinued the rivastigmine oral solution due to poor compliance or preference.
Twelve out of 99 patients (12.1%) reported possible side effects. Among 87 patients, the mean age was 77.2 ± 9.0 years ago with female predominant (65.2%). The optimal dose was 3.6 ± 1.4 ml in average and 4 ml (n = 31, 35.6%) in mode. The duration to optimal dose was 12.5 ± 10.2 weeks and 24 weeks (n = 35, 40.2%) in mode. It presented 25% with cognitive decline in MMSE, 27% with global function decline in CDR and 63% with global function decline in CDR-SB.
Conclusion: We demonstrated the clinical experience of rivastigmine oral solution in mild to moderate AD patients.
It suggested rivastigmine oral solution 4ml is the optimal dose with 24 weeks to the optimal dose for at least one third of patients.
목차
등록된 정보가 없습니다.
참고문헌 (2)
참고문헌 신청
1997 / Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. American Psychiatric Association / Am J Psychiatry 154(5 Suppl):1~39
Ali Hosseini-Sharifabad / 2020 / Magnesium Increases the Protective Effect of Citicoline on Aluminum Chloride-induced Cognitive Impairment / Clinical Psychopharmacology and Neuroscience 18(2):241~248
Ali Hosseini-Sharifabad / 2020 / Magnesium Increases the Protective Effect of Citicoline on Aluminum Chloride-induced Cognitive Impairment / Clinical Psychopharmacology and Neuroscience 18(2):241~248
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Factors Influencing Skin Tolerability to the Rivastigmine Patch in Patients with Alzheimer’s Disease
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
-
알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과
생물치료정신의학
2021 .02
-
Atypical Presentation of Acetylcholinesterase Inhibitor-Induced Diarrhea in Older Adults with Cognitive Decline: An Aspect not to be Underestimated
Annals of geriatric medicine and research
2023 .03
-
The Impact of the COVID-19 Pandemic and Social Distancing on Cognition of Alzheimer’s Disease Patients
PSYCHIATRY INVESTIGATION
2022 .11
-
Clinical Dementia Rating Orientation Score as an Excellent Predictor of the Progression to Alzheimer’s Disease in Mild Cognitive Impairment
PSYCHIATRY INVESTIGATION
2017 .07
-
Effect of Dietary Habits on Alzheimer’s Disease Progression
Yonsei Medical Journal
2024 .04
-
The Effect of Cognitive Training in a Day Care Center in Patients with Early Alzheimer’s Disease Dementia: A Retrospective Study
PSYCHIATRY INVESTIGATION
2020 .01
-
초기 인지저하 단계에서 변화가 확인되는 신경심리영역
노인정신의학
2021 .10
-
The Clinical Characteristics according to the Educational Level in the Elderly Patients with Mild Alzheimer’s Disease Dementia
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
-
뇌졸중 환자를 대상으로 한 인지선별검사(CIST), 한국판 간이정신상태검사 2판(K-MMSE~2) 및 임상치매척도(CDR)의 상관성
재활치료과학
2022 .05
-
치매의 약물요법
대한의사협회지
2018 .01
-
History of Alzheimer’s Disease
Dementia and Neurocognitive Disorders(대한치매학회지)
2016 .12
-
The Association of Blood-Based Inflammatory Factors IL-1β, TGF-β and CRP with Cognitive Function in Alzheimer’s Disease and Mild Cognitive Impairment
PSYCHIATRY INVESTIGATION
2021 .01
-
알츠하이머병의 최신지견
생물정신의학
2016 .01
-
Visual Hallucinations and Amyloid Deposition in Parkinson’s Disease Dementia: A Case Report
PSYCHIATRY INVESTIGATION
2016 .01
-
Comparison of Oral Health Promotion and Dementia Prevention Behavior according to the Perception Level on the Relationship between Them
치위생과학회지
2020 .01
-
Validity of the Tablet-Based Digital Cognitive Test (SCST) in Identifying Different Degrees of Cognitive Impairment
Journal of Korean Medical Science
2024 .09
-
알츠하이머병과 경도인지장애에서 체질량지수와 인지기능과의 연관성
정신신체의학
2016 .01
-
Improvement of Cognitive Function after Computer-Based Cognitive Training in Early Stage of Alzheimer’s Dementia
Dementia and Neurocognitive Disorders(대한치매학회지)
2017 .01
-
훈련 받은 치매파트너가 지역사회 거주 경도인지장애 및 치매환자에게 수행한 인지건강워크북의 유효성
노인정신의학
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0